Overview

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Status:
Not yet recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements

Phase:

Phase 2

Details

Lead Sponsor:

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Treatments:

Atezolizumab